HDAC9 and neoplasm: Interestingly, it suggested that HDAC inhibitor could also improve the anti-tumor effects of other approved multi-kinase inhibitors such as lenvatinib, which indicated that the crosstalk between autophagy and glycolysis may also play pivotal roles in a lenvatinib-resistant mechanism (Roberts et al., 2020).